Sanofi/Re­gen­eron win a new tri­al on Pralu­ent patents; Bridge­Bio bankrolls $30M biotech start­up

→  Af­ter com­ing per­ilous­ly close to see­ing their PC­SK9 drug Pralu­ent jerked off the mar­ket, Sanofi and Re­gen­eron have won a new tri­al in the case in­volv­ing a ri­val drug at Am­gen. An ap­peals court is giv­ing their at­tor­neys a green light to raise is­sues re­gard­ing the va­lid­i­ty of the patents.

→ Bridge­Bio is bankrolling a biotech start­up to the tune of $30 mil­lion. Part­ner­ing with MD An­der­son, the start­up — dubbed Navire Phar­ma — will fund work on in­hibit­ing SHP2 in fight­ing can­cer tu­mors. Shafique Vi­rani, a busi­ness de­vel­op­ment ex­ec at Roche/Genen­tech, has been named the new CEO. “Navire’s com­pounds po­tent­ly bind SHP2 and pre­vent ac­ti­va­tion of the pro­tein, block­ing its abil­i­ty to pro­mote tu­mor growth,” said Vi­rani.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER